No price history available.
Key financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CNYm | 3,402 | 5,550 | 9,062 | 5,868 | 4,643 | 3,532 | N/A | N/A |
| Operating profit | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | CNYm | 589 | 1,479 | 2,316 | 1,439 | 779 | 657 | N/A | N/A |
| EPS reported | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Anhui Guangxin Agrochemical Co., Ltd. researches, develops, produces, and sells pesticides technical, preparations, and intermediates in China. It offers fungicides, such as thiophanate-methyl, pyraclostrobin, imazalil, carbendazim, benomyl, and azoxystrobin; herbicides comprising glyphospphate, isoproturon, hexazinone, and diuron; and insecticides, including thiamethoxam, imidacloprid, and chlorpyrifos. The company also provides phosgene intermediates, including o-hydoxybenzonitrile, p-nitrochlorobrnzene, o-nitrochlorobenzene, o-nitroaniline, 2-cyanophenol, phosphorus trichloride, methyl carbamate, o-phenylenediamine, 3,4-dichlorophenyl isocyanate, and ethyl chloroformate; and medicine and new materials consisting of p-nitrophenol sodium salt, p-nitrophenol, and para-aminophenol. It exports its products to Europe, America, Southeast Asia, and internationally. The company was founded in 2000 and is headquartered in Xuancheng, China.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Anhui Guangxin Agrochemical Co., Ltd. (603599.SS)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Anhui Guangxin Agrochemical Co., Ltd. researches, develops, produces, and sells pesticides technical, preparations, and intermediates in China. It offers fungicides, such as thiophanate-methyl, pyraclostrobin, imazalil, carbendazim, benomyl, and azoxystrobin; herbicides comprising glyphospphate, isoproturon, hexazinone, and diuron; and insecticides, including thiamethoxam, imidacloprid, and chlorpyrifos. The company also provides phosgene intermediates, including o-hydoxybenzonitrile, p-nitrochlorobrnzene, o-nitrochlorobenzene, o-nitroaniline, 2-cyanophenol, phosphorus trichloride, methyl carbamate, o-phenylenediamine, 3,4-dichlorophenyl isocyanate, and ethyl chloroformate; and medicine and new materials consisting of p-nitrophenol sodium salt, p-nitrophenol, and para-aminophenol. It exports its products to Europe, America, Southeast Asia, and internationally. The company was founded in 2000 and is headquartered in Xuancheng, China.